OncoCyte Corp (LTS:0KCC)

$ 2.9 0.1335 (4.83%) Market Cap: 36.62 Mil Enterprise Value: 34.38 Mil PE Ratio: 0 PB Ratio: 1.96 GF Score: 26/100

Q1 2024 OncoCyte Corp Earnings Call Transcript
May 15, 2024

$2.88

Earnings
Q4 2023 OncoCyte Corp Earnings Call Transcript
Apr 12, 2024

$4.96 (+62.09%)

Earnings
Q3 2023 OncoCyte Corp Earnings Call Transcript
Nov 09, 2023

$2.55 (+10.15%)

Earnings
Q2 2023 OncoCyte Corp Earnings Call Transcript
Aug 10, 2023

$3.85

Earnings
OncoCyte Corp Extraordinary Shareholders Meeting Transcript
Jul 24, 2023
OncoCyte Corp Annual Shareholders Meeting Transcript
Jun 23, 2023
Q1 2023 OncoCyte Corp Earnings Call Transcript
May 11, 2023

$5.28

Earnings
Q4 2022 OncoCyte Corp Earnings Call Transcript
Apr 03, 2023

$5.2

Earnings
Q3 2022 OncoCyte Corp Earnings Call Transcript
Nov 10, 2022

$13.56

Earnings
OncoCyte Corp at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Aug 11, 2022
Q2 2022 OncoCyte Corp Earnings Call Transcript
Aug 10, 2022

$17.17 (-5.39%)

Earnings
OncoCyte Corp DetermalO™ and Tumor Microenvironment in Clinical Practice Key Opinion Leader Transcript
Jun 28, 2022
Q1 2022 OncoCyte Corp Earnings Call Transcript
May 11, 2022

$22.8

Earnings
Q4 2021 OncoCyte Corp Earnings Call Transcript
Mar 10, 2022

$34.4

Earnings
OncoCyte Corp to Discuss Development and Co-Marketing Agreement with Thermo Fisher Scientific Inc Call Transcript
Jan 18, 2022
OncoCyte Corp Investor and Analyst Day Transcript
Dec 14, 2021
Q3 2021 OncoCyte Corp Earnings Call Transcript
Nov 09, 2021

$69.9 (+2.75%)

Earnings
OncoCyte Corp Key Opinion Leader Presentation Part 2: DetermaIO™ in Triple-Negative Breast Cancer Transcript
Sep 28, 2021
OncoCyte Corp Key Opinion Leader Presentation Part 1: Transplant Rejection Testing Transcript
Sep 22, 2021
Q2 2021 OncoCyte Corp Earnings Call Transcript
Aug 10, 2021

$102

Earnings
OncoCyte Corp Annual Shareholders Meeting Transcript
Jun 24, 2021
Q1 2021 OncoCyte Corp Earnings Call Transcript
May 17, 2021

$79.4

Earnings
OncoCyte Corp DetermaIO™ Data KOL Webinar Transcript
Apr 19, 2021
Q4 2020 OncoCyte Corp Earnings Call Transcript
Mar 16, 2021

$96.76 (-0.04%)

Earnings
Q3 2020 OncoCyte Corp Earnings Call Transcript
Nov 12, 2020

$26.2

Earnings
OncoCyte Corp - EGFR And Molecular Risk Stratification In Early-Stage NSCLC Transcript
Oct 22, 2020
OncoCyte Corporation - Special Call Transcript
Aug 19, 2020
Q2 2020 OncoCyte Corp Earnings Call Transcript
Jul 29, 2020

$26.2

Earnings
OncoCyte Corp Announces Completion Of Determadx™ Clinical Validation Study Transcript
Jun 29, 2020
OncoCyte Corp Annual Shareholders Meeting Transcript
Jun 17, 2020
Q1 2020 OncoCyte Corp Earnings Call Transcript
May 12, 2020

$46.56

Earnings
Q4 2019 OncoCyte Corp Earnings Call Transcript
Mar 25, 2020

$46.56

Earnings
OncoCyte Corp to Acquire Insight Genetics Inc - Conference Call Transcript
Jan 10, 2020
Q3 2019 OncoCyte Corp Earnings Call Transcript
Nov 14, 2019

$40

Earnings
Q2 2019 OncoCyte Corp Earnings Call Transcript
Aug 14, 2019

$40

Earnings

Q2 2022 OncoCyte Corp Earnings Call Transcript

Aug 10, 2022 / 08:30PM GMT

Release Date Price: $17.17 (-5.39%)

Transcript 10-Q8-K

Operator

Good day, and welcome to the OncoCyte Conference Call to discuss the Second Quarter 2022 Financial Results. Today's call is being recorded.

At this time, I would like to turn the call over to Caroline Corner, Westwicke Investor Relations. Please go ahead.

Caroline V. Corner

Westwicke Partners, LLC - MD

Thank you, operator, and thank you, everyone, for joining us on today's conference call to discuss OncoCyte's second quarter 2022 financial results. If you've not seen today's financial press releases, please visit the company's website on the Investors page. Joining me on today's call are Ronnie Andrews, President and Chief Executive Officer; and Anish John, Chief Financial Officer.

I would like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. We encourage you to review the company's SEC filings, including, without limitation, the company's Form 10-K and 10-Qs, which identify the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.